Context on Qiagen’s recent share performance

Qiagen (QGEN) has drawn attention after a run of weaker returns, with the stock down about 3% over the past week, 16% over the past month, and 34% over the past 3 months.

Qiagen’s share price has lost momentum over 2024, with the recent 16.5% 1 month share price return and 34.2% 3 month share price return both negative, contributing to a 20.2% negative 1 year total shareholder return.

If Qiagen’s recent pullback has you reassessing your watchlist, it may be worth scanning for other healthcare and diagnostics ideas using our 35 healthcare AI stocks

So with Qiagen’s share price pulling back while the stock trades below some analyst value estimates, and the company reporting annual revenue of about US$2.1b and net income of roughly US$402m, is there a buying opportunity here or is the market already pricing in future growth?

Most Popular Narrative: 37.4% Undervalued

Qiagen’s most followed narrative pegs fair value at $53.53, well above the last close of $33.51. This frames the recent sell off as a valuation gap.

The accelerated adoption of automation and digital workflows in both clinical and research settings, as seen with the development and imminent launch of three new high-throughput, digitally-connected automated sample prep systems, positions Qiagen to address increasing throughput and efficiency needs, supporting both top-line growth and operating margin improvement in coming years.

Want to see what sits behind that optimism on automation, recurring consumables, and profit margins, and how it all flows into a higher future earnings base and valuation multiple?

Result: Fair Value of $53.53 (UNDERVALUED)

However, you still need to weigh softer life sciences spending and rising competition in syndromic testing, which could pressure margins and challenge the upbeat automation story.

Next Steps

With sentiment clearly split between risks and rewards, this is the moment to look through the data yourself and decide where you stand, starting with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Qiagen has sharpened your thinking, do not stop here; broaden your watchlist with fresh stock ideas that match the kind of portfolio you want to build.

• Target cash rich resilience by scanning companies highlighted in the solid balance sheet and fundamentals stocks screener (44 results) for balance sheet strength and fundamentals that can support a steadier ride.
• Hunt for potential value gaps by checking the 51 high quality undervalued stocks and see which companies currently trade below what their underlying numbers may suggest.
• Prioritise income by reviewing the 12 dividend fortresses and spot stocks offering higher yields that could help anchor your portfolio with regular cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.